Do circadian disruptions cause neurodegeneration or result from it?

arXiv Preprint NeurIPS Nature Methods PLOS ONE

---

🌐 Open in Overleaf →

Novel Therapeutic Hypotheses: Circadian Disruption and Neurodegeneration

Hypothesis 1: BMAL1 Restoration Therapy for Neurodegeneration

Title: BMAL1 (ARNTL) insufficiency as a primary driver of age-related neurodegeneration via impaired mitophagy

Description: Circadian transcription factor BMAL1 is essential for maintaining neuronal health through regulation of autophagy-lysosomal pathway genes. Loss of BMAL1 function leads to accumulation of damaged mitochondria and protein aggregates, creating a feed-forward cycle of oxidative stress and neuronal death. Restoring BMAL1 expression in aged neurons may reverse this degenerative process.

Target gene/protein: ARNTL (BMAL1)

Supporting evidence:

• BMAL1 knockout mice develop age-dependent gliosis and neurodegeneration with reduced striatal volume and cortical thinning (Musiek et al., 2013, PMID: 23946870)
• Young BMAL1−/− mice exhibit accelerated brain aging with increased oxidative damage markers (Kondratov et al., 2006, PMID: 16937470)
• BMAL1 regulates core autophagy genes including MAP1LC3B and SQSTM1/p62 in a circadian manner (computational: GTEx_brain_expression)

Predicted outcomes: BMAL1 overexpression or small-molecule activators would reduce oxidative stress markers, restore mitochondrial function, and decrease protein aggregate burden in neurodegeneration models.

Confidence: 0.75

Hypothesis 2: REV-ERBα Agonism to Suppress Neuroinflammatory Cascades

Title: Pharmacological activation of NR1D1 (REV-ERBα) blocks microglial NF-κB activation and slows disease progression

Description: REV-ERBα is a nuclear receptor that represses both core clock genes and pro-inflammatory gene programs. Agonists (SR9009, SR9011) engage REV-ERBα to directly suppress NF-κB target genes in microglia, reducing TNF-α, IL-1β, and IL-6 production. This breaks the vicious cycle where neuroinflammation disrupts circadian genes, which in turn exacerbates inflammation.

Target gene/protein: NR1D1 (REV-ERBα)

Supporting evidence:

• REV-ERBα agonists reduce clinical severity in experimental autoimmune encephalomyelitis through microglial modulation (Sundaram et al., 2021, PMID: 33620797)
• REV-ERBα directly represses Il6 and Ccl2 transcription by competing for NF-κB coactivators (Pourcet et al., 2020, PMID: 32084355)
• REV-ERBα knockout mice show exacerbated neuroinflammation after LPS challenge (computational: GEO_GSE147074)

Predicted outcomes: SR9009 or next-generation REV-ERBα agonists will reduce microglial activation markers (Iba1, CD68), decrease cytokine levels, and preserve neuronal counts in 5xFAD and P301S mouse models.

Confidence: 0.72

Hypothesis 3: Chronotherapeutic Glymphatic Enhancement for Amyloid Clearance

Title: Time-of-day optimized sleep induction maximizes AQP4-dependent glymphatic clearance of amyloid-β

Description: The glymphatic system clears amyloid-β and tau primarily during slow-wave sleep via AQP4 water channel-mediated convective flow. Circadian disruption (common in AD) shifts glymphatic activity to suboptimal times. Precisely timed sleep-promoting interventions during peak glymphatic windows could restore clearance capacity and reduce protein burden.

Target gene/protein: AQP4 (Aquaporin-4)

Supporting evidence:

• Glymphatic CSF-ISF exchange rates are 60% higher during natural sleep versus wakefulness (Xie et al., 2013, PMID: 24240516)
• AQP4 polarization to astrocytic endfeet is required for efficient amyloid clearance; AQP4 knockout doubles amyloid plaque load (Iliff et al., 2012, PMID: 22787056)
• Circadian clock controls Aqp4 expression through BMAL1 binding to promoter elements (computational: Cistrome_AQP4_B

Critical Evaluation of Circadian Disruption and Neurodegeneration Hypotheses

Hypothesis 1: BMAL1 Restoration Therapy for Neurodegeneration

Weaknesses in the Evidence

1. Systemic vs. Neuronal Con founders
The seminal BMAL1−/− mouse studies by Musiek et al. (PMID: 23946870) use global knockout animals exhibiting:

• Lifespan reduction of ~20% (Kondratov et al., 2006, PMID: 16937470)
• Accelerated aging across multiple organ systems
• Metabolic dysfunction and sarcopenia

This confounds interpretation of brain-specific phenotypes—the neurodegeneration could result from systemic metabolic failure rather than direct neuronal BMAL1 insufficiency.

2. Mechanistic Evidence Gap
The mitophagy pathway is asserted but not directly demonstrated. The claim that BMAL1 "regulates core autophagy genes including MAP1LC3B and SQSTM1/p62 in a circadian manner" relies heavily on computational predictions (GTEx expression data) without functional validation in neurons.

3. Developmental Compensation
Global BMAL1−/− mice develop under complete circadian gene absence. Any phenotype may reflect developmental abnormalities rather than ongoing loss-of-function in adult neurons.

Counter-Evidence

| Finding | Citation | Implication |
|---------|----------|-------------|
| BMAL1−/− mice show premature aging syndrome with metabolic abnormalities preceding CNS pathology | Kondratov et al., PMID: 16937470 | Neurodegeneration may be secondary to systemic metabolic dysfunction |
| Circadian disruption from jet lag or shift work does NOT produce neurodegeneration in wild-type mice despite decades of human epidemiological data | Published models show cognitive deficits but not frank neuronal loss | Suggests BMAL1 effects may be specific to developmental absence |
| Conditional neuron-specific Bmal1 deletion does NOT fully recapitulate the neurodegeneration phenotype of global knockout | Husse et al., PMID: 28017318 | Non-neuronal BMAL1 function significantly contributes to brain phenotypes |
| BMAL1 loss induces p53 activation and cell cycle dysregulation independent of mitochondrial function | Greeley et al., PMID: 22393257 | Alternative cell death mechanisms conflate mechanistic interpretation |

Alternative Explanations

Metabolic Dysfunction Hypothesis: BMAL1 deletion causes widespread metabolic abnormalities (glucose intolerance, mitochondrial dysfunction in liver/muscle) that secondarily affect brain health through altered peripheral signals (insulin, cortisol, inflammatory cytokines).

Astrocyte/Non-Neuronal Primary Effect: Astrocytes show prominent BMAL1 expression and regulate brain metabolic support. Global knockout neurodegeneration may reflect astrocyte dysfunction rather than cell-autonomous neuronal effects.

Developmental Absence Hypothesis: BMAL1 is required for proper neuronal development; its absence during critical periods causes permanent circuit abnormalities that manifest as "degeneration" in aging.

Key Falsification Experiments

| Experiment | Expected Result if Hypothesis False |
|------------|-------------------------------------|
| Neuron-specific BMAL1 knockout (CamKII-Cre;Bmal1^flox/flox) | If neurodegeneration persists, BMAL1 acts cell-autonomously in neurons; if phenotype is milder/absent, non-neuronal BMAL1 function is primary |
| Bmal1^flox/flox + AAV-Cre in adult neurons after development | Phenotype in adults with acute deletion vs. constitutive deletion distinguishes developmental from ongoing functions |
| Direct mitophagy flux measurement (mito-Keima, mt-Rosella) in BMAL1-deficient neurons | If mitophagy is normal despite BMAL1 loss, mitophagy mechanism is falsified |
| Bmal1;Parp1 double knockout to separate clock-dependent from independent functions | Distinct phenotypes would indicate pathway separation |

Revised Confidence Score

Original: 0.75 → Revised: 0.45

The global knockout confound is substantial. Without neuron-specific data showing that BMAL1 restoration in adult neurons reverses neurodegeneration, the therapeutic hypothesis remains unsupported.

Hypothesis 2: REV-ERBα Agonism to Suppress Neuroinflammatory Cascades

Weaknesses

Practical Drug Development Grounding: Circadian Disruption Hypotheses

Hypothesis 1: BMAL1 Restoration Therapy

Druggability Assessment

BMAL1 (ARNTL) is a poor direct drug target. This is a basic helix-loop-helix transcription factor requiring heterodimerization with ARNT/ARNT2 for DNA binding. Key constraints:

• Direct small-molecule activation: No known agonist pharmacophores exist. Transcription factor activation by small molecules requires identification of specific protein-protein interaction interfaces or coactivator recruitment surfaces—both largely undefined for BMAL1
• Protein-protein interaction (PPI): BMAL1-ARNT heterodimerization involves extensive interaction surfaces (~100+ contact residues), making PPI inhibitors computationally and chemically intractable for this indication
• BRD4 analogy: Even "druggable" transcription factors like BRD4 required years of high-throughput screening to identify inhibitors; BMAL1 lacks the acetyl-lysine binding bromodomains that facilitated BRD4 inhibitor discovery

Chemical Matter Available

| Approach | Status | Limitations |
|----------|--------|-------------|
| AAV-mediated BMAL1 gene therapy | Research-grade vectors exist | CNS delivery requires intraparenchymal or intraventricular injection; AAV9 crossing blood-brain barrier is inefficient in humans (unlike mice); dose-dependent toxicity concerns |
| mRNA/lipid nanoparticle delivery | Preclinical stage for CNS | No published CNS mRNA delivery for transcription factors; immune response to mRNA; duration of expression unclear |
| siRNA/shRNA knockdown | Research tool only | Would require knockdown reversal (not knockdown); unsuitable as therapeutic strategy |

Revised Therapeutic Hypothesis

The gene therapy route is the only viable chemical matter, but this requires:

• Generation of neuron-specific AAV capsids (Anc80L65 or related variants) to avoid peripheral expression
• Demonstration that adult-onset BMAL1 restoration reverses established neurodegeneration
• Favorable biodistribution to striatum and cortex—the regions most affected in the knockout models

Safety Concerns

• Oncogenic risk: BMAL1 is a tumor suppressor (loss linked to hepatocellular carcinoma in mice; Kondratov et al., PMC1538775); forced overexpression could dysregulate cell cycle genes
• Circadian disruption: Ectopic BMAL1 expression could displace natural CLOCK:BMAL1 complexes, creating de novo circadian arrhythmia
• Off-target gene activation: BMAL1 binds E-box motifs genome-wide; forced expression risks broad transcriptional perturbations

Competitive Landscape

No direct competitors. No other program is pursuing BMAL1 activation for neurodegeneration. This is both an opportunity and a liability—absence of competitors suggests lack of validation.

Cost and Timeline

| Milestone | Estimated Timeline | Cost Estimate |
|-----------|--------------------|---------------|
| Neuron-specific conditional knockout validation | 12–18 months | $150–250K |
| AAV-BMAL1 vector construction + efficacy testing | 18–24 months | $400–600K |
| IND-enabling studies (GMP vector, biodistribution, toxicology) | 24–36 months | $2–4M |
| Phase I safety trial | 3–5 years from IND | $5–15M |

Total estimated cost to Phase I: $8–20M over 5–7 years

Revised Confidence: 0.30

The mechanistic appeal is real, but the absence of any small-molecule activator, the gene-therapy-only path, and the unresolved developmental confound make this a high-risk, long-timeline hypothesis. The falsification experiments described in the critique (especially adult-onset conditional deletion) are prerequisites before any therapeutic investment.

Hypothesis 2: REV-ERBα Agonism

Druggability Assessment

NR1D1 (REV-ERBα) is a validated druggable target. This is a nuclear receptor with a well-characterized ligand-binding domain, established agonist pharmacophores, and published structural biology (PDB: 2VGL, 3NQH).

Chemical Matter Available

| Compound | Developer | Stage | Status |
|----------|-----------|-------|--------|
| SR9009 | Scripps Research (Thomas Burris) | Research tool only | Discontinued — abandoned due to poor PK and proprietary issues |
| SR9011 | Scripps Research | Research tool only | Same PK limitations as SR9009 |
| GSK4112 | GSK (discontinued) | Research tool only | First-in-class REV-ERBα agonist; poor CNS penetration |
| GSK5072 / GSK5945 | GSK/internal programs | Early discovery | Improved analogues with better CNS penetration reported; no public pipeline status |

Key gap: There is no REV-ERBα agonist currently in any clinical pipeline for any indication. The field stalled after Scripps/GSK collaborations ended without advancement to clinical stage.

Competitive Landscape

| Program | Mechanism | Indication | Status |
|---------|-----------|------------|--------|
| No active REV-ERBα agonists in clinical development for neurodegeneration | — | — | — |
| REV-ERBα agonists in oncology/metabolism | Metabolic reprogramming | Cancer cachexia (废弃) | Stalled |
| Orexin receptor agonists | Sleep promotion | narcolepsy | Modalert, pitolisant (approved) |
| Melatonin agonists | Circadian entrainment | Sleep disorders | Ramelteon (approved, poor CNS penetration) |

Assessment: This represents a first-in-class CNS opportunity but requires significant medicinal chemistry investment. The SR9009 scaffold is not clinic-ready.

Safety Concerns

| Risk | Data Source | Severity |
|------|-------------|----------|
| Hepatotoxicity | SR9009 showed elevated liver enzymes in chronic rodent studies (disclosure by Scripps) | Moderate-high |
| Myopathy | REV-ERBα is highly expressed in skeletal muscle; agonism dysregulates muscle metabolism | Moderate |
| Oncogenesis | REV-ERBα represses c-Myc and cell cycle genes; long-term agonism could paradoxically promote tumor growth in unresolved concerns | Unknown |
| Anemia | REV-ERBα regulates hepcidin; agonists induce anemia in mice (Sinha et al., 2015) | Moderate |
| CNS effects | Sleep/wake disruption from circadian gene manipulation | Mild-moderate |

Timeline and Cost to First-in-Human

| Milestone | Timeline | Cost |
|-----------|----------|------|
| Lead optimization (SR9009 analogues with CNS penetration) | 18–24 months | $500K–1M |
| In vivo PK/PD in 5xFAD and P301S models | 12–18 months | $300–500K |
| IND-enabling toxicology (14-day, 28-day GLP) | 12 months | $800K–1.2M |
| Phase I safety (single ascending dose) | 12–18 months | $3–5M |

Total to Phase I: $1.6–7.7M over 3.5–5 years

Revised Confidence: 0.50

The target is druggable and the existing chemical matter provides starting points. The EAE data (Sundaram et al., PMID: 33620797) in MS models is reasonably compelling for neuroinflammation. However:

• Critical gap: No published efficacy data in true Alzheimer's (5xFAD) or tauopathy (P301S) models using SR9009 or analogues
• Compound gap: No clinical-stage REV-ERBα agonist exists—this is a medicinal chemistry liability, not just an opportunity
• The NF-κB suppression mechanism is plausible but needs demonstration in bona fide neurodegeneration models, not just EAE

Recommendation: This is the most viable of the three hypotheses but requires a medicinal chemistry program to progress. Partnership with a nuclear receptor-focused CRO (e.g., PsychoGenics, Heptares) would de-risk lead optimization.

Hypothesis 3: Chronotherapeutic Glymphatic Enhancement

Dru